Cerenome (PSTV) Net Equity Issued and Repurchased (2010 - 2025)

Plus Therapeutics (PSTV) has reported Net Equity Issued and Repurchased for 15 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $19.8 million (up 1675.52% YoY), while the FY2025 annual figure was $22.6 million, up 211.29% from the prior year.
• Net Equity Issued and Repurchased declined to $3.0 million in Q4 2025 per PSTV's latest filing, from $16.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $16.8 million in Q3 2025 and bottomed at -$6.2 million in Q4 2021.
• Historically, Net Equity Issued and Repurchased has averaged $3.4 million across 4 years, with a median of $3.1 million in 2022.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased slumped 253.86% — and 2023, when it jumped 4296.77%.
• Plus Therapeutics' Net Equity Issued and Repurchased stood at -$6.2 million in 2021, then soared by 151.91% to $3.2 million in 2022, then tumbled by 68.75% to $1.0 million in 2023, then surged by 200.3% to $3.0 million in 2025.
• Business Quant data shows PSTV's Net Equity Issued and Repurchased at $3.0 million in Q4 2025, $16.8 million in Q3 2025, and $1.0 million in Q4 2023.